11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
1 citations
,
January 2025 in “Dermatologic Therapy” Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
12 citations
,
November 2017 in “European Annals of Allergy and Clinical Immunology” Omalizumab can cause temporary hair loss but still works well for chronic urticaria.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” A new cream, DHMEQ, reduces allergic skin inflammation effectively.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
1 citations
,
January 2021 in “Skin appendage disorders” A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
51 citations
,
August 2015 in “Cochrane library” Methotrexate is not proven to maintain remission in ulcerative colitis.
29 citations
,
December 2022 in “Journal of Nanobiotechnology” Stem cell vesicles reduced eczema symptoms in mice safely.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
34 citations
,
January 2023 in “Therapeutic Advances in Medical Oncology” Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
3 citations
,
September 2021 in “JAAD case reports” Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.